CNS Pharmaceuticals (CNSP) Projected to Post Earnings on Monday

CNS Pharmaceuticals (NASDAQ:CNSP) is projected to post its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect CNS Pharmaceuticals to post earnings of ($5.37) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

CNS Pharmaceuticals Stock Down 6.2%

Shares of CNSP opened at $2.56 on Friday. The company has a market cap of $1.59 million, a price-to-earnings ratio of -0.08 and a beta of 2.70. CNS Pharmaceuticals has a twelve month low of $2.06 and a twelve month high of $34.80. The company has a 50 day moving average of $3.95 and a two-hundred day moving average of $6.20.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Hedge Funds Weigh In On CNS Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals in the 2nd quarter valued at approximately $335,000. Boothbay Fund Management LLC purchased a new stake in CNS Pharmaceuticals during the 4th quarter worth approximately $71,000. Finally, Ikarian Capital LLC purchased a new stake in CNS Pharmaceuticals during the 4th quarter worth approximately $241,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.